Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. It has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. 

Type
Public
HQ
Hopkinton, US
Founded
2002
Size (employees)
15 (est)
Spring Bank Pharmaceuticals was founded in 2002 and is headquartered in Hopkinton, US
Report incorrect company information

Spring Bank Pharmaceuticals Office Locations

Spring Bank Pharmaceuticals has offices in Milford and Hopkinton
Hopkinton, US (HQ)
86 South St
Milford, US
113 Cedar St
Show all (2)
Report incorrect company information

Spring Bank Pharmaceuticals Financials and Metrics

Spring Bank Pharmaceuticals Revenue

USD

Net income (Q1, 2018)

(4.9 m)

EBIT (Q1, 2018)

(6.2 m)

Market capitalization (11-Jul-2018)

148.5 m

Closing share price (11-Jul-2018)

11.3

Cash (31-Mar-2018)

23.8 m
Spring Bank Pharmaceuticals's current market capitalization is $148.5 m.
Annual
USDFY, 2016

General and administrative expense

5.7 m

R&D expense

14 m

Operating expense total

19.8 m

EBIT

(19.4 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

1.2 m1.5 m1.5 m2 m1.9 m2.2 m

R&D expense

5.6 m2.9 m2.7 m2.5 m3.4 m4 m

Operating expense total

6.8 m4.4 m4.2 m4.5 m5.3 m6.2 m

EBIT

(6.5 m)(4.3 m)(4.2 m)(4.5 m)(5.3 m)(6.2 m)
Annual
USDFY, 2016

Cash

10.7 m

Accounts Receivable

57.4 m

Inventories

840 k

Current Assets

25.6 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

1.9 m11.3 m5.3 m14 m51.4 m23.8 m

Current Assets

7.2 m20.7 m16.7 m21.6 m57.3 m47.8 m

PP&E

498 k523 k496 k586 k550 k892 k

Accounts Payable

1.3 m2.9 m2.3 m1.9 m1.8 m1.7 m
Annual
USDFY, 2016

Net Income

(17.4 m)

Depreciation and Amortization

118 k

Inventories

(527 k)

Accounts Payable

(812 k)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(6.5 m)(10.8 m)(15 m)(6.5 m)(15.4 m)(4.9 m)

Depreciation and Amortization

26 k57 k87 k36 k76 k45 k

Accounts Payable

(840 k)(564 k)148 k519 k432 k(45 k)

Cash From Operating Activities

(4.6 m)(8.9 m)(11.7 m)(4.1 m)(8.8 m)(6.2 m)
Show all financial metrics
Report incorrect company information

Spring Bank Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Spring Bank Pharmaceuticals Company Life and Culture

Report incorrect company information